Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Osteoarthritis Market Overview

The osteoarthritis market size was valued at $2.5 billion in 2021 and is expected to achieve a CAGR of more than 4% during 2021-2031. OA is a slowly progressive joint disease characterized by degradation of the articular (hyaline) cartilage that coats the bone proximities of synovial joints. Contrary to the previous notion that OA is exclusively a disorder of articular cartilage, studies have demonstrated it is a disease of the whole joint, adversely affecting the subchondral bone, tendons, ligaments, and synovium. Damage to these structures causes irritation and pain, which intensifies with disease progression and can significantly decrease individuals’ quality of life.

Osteoarthritis Market Size

To gain more information on the osteoarthritis market forecast, download a free report sample

The osteoarthritis market research report provides an overview of the risk factors, comorbidities, and global and historical trends for hand OA, knee OA, and hip OA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiological forecast for total prevalent cases and diagnosed prevalent cases of hand OA, knee OA, and hip OA segmented by age (18 years and older) and sex in these markets.

  Market Size (2021)  $2.5 billion
  CAGR (2021 – 2031)  >4%
  Key Segments  Hand OA, Knee OA, and Hip OA
Key Age Segments (Hand OA) 18-19 Years, 20-29 Years, 30-39 Years, 40-49 Years, 50-59 Years, 60-69 Years, 70-79 Years, and Above 80 years
Key Sex Segments (Hand OA) Men and Women
  Leading Players Pfizer, Janssen, GlaxoSmithKline, Bayer, Novartis, Eli Lilly, Merck, Pacira BioSciences, Kolon TissueGene, Biosplice Therapeutics, Organogenesis Holdings, Techfields Pharma, and Centrexion Therapeutics

Osteoarthritis Market Drivers

The major drivers of growth in the osteoarthritis market include the launch of new biologic therapies priced at a substantial premium. The launch of drugs with novel mechanisms of action (MOAs) and disease-modifying effects will shift the treatment regimen towards using patented new drugs, which will also increase the OA market value. Moreover, recent improvements in imaging techniques will facilitate the development of disease-modifying osteoarthritis drugs (DMOADs) and encourage early intervention.

Osteoarthritis Market by Key Segments

The osteoarthritis market can be further segmented into hand OA, knee OA, and hip OA.

For more insights into the segments, download a free report sample

Hand OA Market Segmentation by Age

The hand OA market can be segmented based on age into 18-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and above 80 years.

In 2021, for the 7MM combined, the highest number of diagnosed prevalent cases (symptomatic) was in the age group 60–69 years.

Hand OA Market Analysis by Age

Hand OA Market Analysis by Age

For more age segment insights into the hand OA market, download a free report sample

Hand OA Market Segmentation by Sex

The hand OA market can be segmented based on sex into men and women. In the 7MM combined, the number of diagnosed prevalent cases of osteoarthritis was higher in women than in men in 2021. The differences in the numbers of diagnosed prevalent cases (symptomatic) of hand OA across the sexes and markets may be mostly attributed to differences in the underlying demographic differences in each market, as well as the significant differences in sex-specific diagnosed prevalence.

Hand OA Market Analysis by Sex

Hand OA Market Analysis by Sex

For more sex segment insights into the hand OA market, download a free report sample

Hand OA Market Competitive Landscape

Some of the leading players in the osteoarthritis market are Pfizer, Janssen, GlaxoSmithKline, Bayer, Novartis, Eli Lilly, Merck, Pacira BioSciences, Kolon TissueGene, Biosplice Therapeutics, Organogenesis Holdings, Techfields Pharma, and Centrexion Therapeutics.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global OA therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global OA market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global OA therapeutics market from 2021-2031.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Pfizer
Janssen
GlaxoSmithKline
Bayer
Novartis
Eli Lilly
Merck
Pacira BioSciences
Kolon TissueGene
Biosplice Therapeutics
Organogenesis Holdings
Techfields Pharma
Centrexion Therapeutics
Regeneron
Xalud Therapeutics
Bone Therapeutics

Table of Contents

| About GlobalData

1 Osteoarthritis: Executive Summary

1.1 OA market expected to experience conservative growth from 2021–31

1.2 New players to enter a saturated field

1.3 Clinical unmet needs and opportunities

1.4 DMOADs to expand OA treatment options

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Symptoms

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources used

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: total prevalent cases (radiographic)

4.4.4 Forecast assumptions and methods: total prevalent cases (symptomatic)

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases (symptomatic)

4.4.6 Forecast assumptions and methods: diagnosed prevalent cases (symptomatic) by severity

4.5 Epidemiological forecast for OA (2021–31)

4.5.1 Total prevalent cases (radiographic) of hand OA

4.5.2 Total prevalent cases (symptomatic) of hand OA

4.5.3 Diagnosed prevalent cases (symptomatic) of hand OA

4.5.4 Age-specific diagnosed prevalent cases (symptomatic) of hand OA

4.5.5 Sex-specific diagnosed prevalent cases (symptomatic) of hand OA

4.5.6 Diagnosed prevalent cases (symptomatic) of hand OA by severity

4.5.7 Total prevalent cases (radiographic) of knee OA

4.5.8 Total prevalent cases (symptomatic) of knee OA

4.5.9 Diagnosed prevalent cases (symptomatic) of knee OA

4.5.10 Age-specific diagnosed prevalent cases (symptomatic) of knee OA

4.5.11 Sex-specific diagnosed prevalent cases (symptomatic) of knee OA

4.5.12 Diagnosed prevalent cases (symptomatic) of knee OA by severity

4.5.13 Total prevalent cases (radiographic) of hip OA

4.5.14 Total prevalent cases (symptomatic) of hip OA

4.5.15 Diagnosed prevalent cases (symptomatic) of hip OA

4.5.16 Age-specific diagnosed prevalent cases (symptomatic) of hip OA

4.5.17 Sex-specific diagnosed prevalent cases (symptomatic) of hip OA

4.5.18 Diagnosed prevalent cases (symptomatic) of hip OA by severity

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of analysis

4.6.4 Strengths of analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.1.1 Diagnosis

5.1.2 Treatment paradigm

5.2 Insights on disease management by location

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Disease-modifying OA drugs to halt the progression of OA

7.3 Analgesics with improved efficacy and safety profiles

7.4 Therapies to treat OA in patients with comorbid conditions

7.5 Improved patient adherence to non-pharmacological treatments

8 R&D Strategies

8.1 Overview

8.1.1 Development of analgesics with novel MOA to improve tolerability and efficacy

8.1.2 Development of a DMOAD

8.1.3 Development of combination therapy

8.1.4 Strategic partnerships

8.2 Clinical trials design

8.2.1 Limitations of pain and patient-reported outcomes as primary outcomes

8.2.2 Lack of consensus on imaging as a primary endpoint in DMOAD trial design

8.2.3 Improved assessment of joint tissue biology

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Analgesic drugs

10.2.2 DMOAD pipeline therapies

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 7MM

12.1.1 Forecast

12.1.2 Drivers and barriers – global (7MM) issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs and payers interviewed for this report

13.4.1 KOLs

13.4.2 Payers

13.5 Primary research – prescriber survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Osteoarthritis: key metrics in the 7MM

Table 2: Etiology of OA

Table 3: Kellgren Lawrence Grading System

Table 4: Risk factors and comorbid conditions associated with OA

Table 5: Severity scoring system for classifying the hand, knee, and hip OA using the KL grading scale

Table 6: Current treatment recommendations for hand, knee, and hip osteoarthritis

Table 7: Current treatment options for osteoarthritis

Table 8: Clinical trial design of key pipeline drugs for osteoarthritis, 2022

Table 9: Top completed deals in OA market by value, 2015–22

Table 10: OA market – global (7MM) drivers and barriers, 2021–31

Table 11: Key events impacting sales for OA in the US, 2021–31

Table 12: OA market – drivers and barriers in the US, 2021–31

Table 13: Key events impacting sales for OA in the 5EU, 2021–31

Table 14: OA market – drivers and barriers in the 5EU, 2021–31

Table 15: Key events impacting sales for OA in Japan, 2021–31

Table 16: OA market – drivers and barriers in Japan, 2021–31

Table 17: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global (7MM) sales forecast by country for osteoarthritis in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in osteoarthritis during the forecast period

Figure 3: Competitive assessment of the late-stage analgesic pipeline agents that GlobalData expects to be licensed for the treatment of osteoarthritis during the forecast period

Figure 4: Competitive assessment of the late-stage DMOAD pipeline agents that GlobalData expects to be licensed for the treatment of osteoarthritis during the forecast period

Figure 5: Main structures of a healthy joint and a joint affected by OA

Figure 6: 7MM, diagnosed prevalence (symptomatic) (%), hand OA, both sexes, ages ≥18 years, 2021

Figure 7: 7MM, diagnosed prevalence (symptomatic) (%), knee OA, both sexes, ages ≥18 years, 2021

Figure 8: 7MM, diagnosed prevalence (symptomatic) (%), hip OA, both sexes, ages ≥18 years, 2021

Figure 9: 7MM, sources used to forecast the total prevalent cases (radiographic), hand OA

Figure 10: 7MM, sources used to forecast the total prevalent cases (radiographic), knee OA

Figure 11: 7MM, sources used to forecast the total prevalent cases (radiographic), hip OA

Figure 12: 7MM, sources used to forecast the total prevalent cases (symptomatic), hand OA

Figure 13: 7MM, sources used and not used to forecast the total prevalent cases (symptomatic), knee OA

Figure 14: 7MM, sources used and not used to forecast the total prevalent cases (symptomatic), hip OA

Figure 15: 7MM, total prevalent cases (radiographic) of hand OA, both sexes, ages ≥18 years, N, 2021

Figure 16: 7MM, total prevalent cases (symptomatic) of hand OA, both sexes, ages ≥18 years, N, 2021

Figure 17: 7MM, diagnosed prevalent cases (symptomatic) of hand OA, both sexes, ages ≥18 years, N, 2021

Figure 18: 7MM, age-specific diagnosed prevalent cases (symptomatic) of hand OA, both sexes, ages ≥18 years, N, 2021

Figure 19: 7MM, sex-specific diagnosed prevalent cases (symptomatic) of hand OA, both sexes, ages ≥18 years, N, 2021

Figure 20: 7MM, diagnosed prevalent cases (symptomatic) of hand OA by severity, both sexes, ages ≥18 years, N, 2021

Figure 21: 7MM, total prevalent cases (radiographic) of knee OA, both sexes, ages ≥18 years, N, 2021

Figure 22: 7MM, total prevalent cases (symptomatic) of knee OA, both sexes, ages ≥18 years, N, 2021

Figure 23: 7MM, diagnosed prevalent cases (symptomatic) of knee OA, both sexes, ages ≥18 years, N, 2021

Figure 24: 7MM, age-specific diagnosed prevalent cases (symptomatic) of knee OA, both sexes, ages ≥18 years, N, 2021

Figure 25: 7MM, sex-specific diagnosed prevalent cases (symptomatic) of knee OA, both sexes, ages ≥18 years, N, 2021

Figure 26: 7MM, diagnosed prevalent cases (symptomatic) of knee OA by severity, both sexes, ages ≥18 years, N, 2021

Figure 27: 7MM, total prevalent cases (radiographic) of hip OA, both sexes, ages ≥18 years, N, 2021

Figure 28: 7MM, total prevalent cases (symptomatic) of hip OA, both sexes, ages ≥18 years, N, 2021

Figure 29: 7MM, diagnosed prevalent cases (symptomatic) of hip OA, both sexes, ages ≥18 years, N, 2021

Figure 30: 7MM, age-specific diagnosed prevalent cases (symptomatic) of hip OA, both sexes, ages ≥18 years, N, 2021

Figure 31: 7MM, sex-specific diagnosed prevalent cases (symptomatic) of hip OA, both sexes, ages ≥18 years, N, 2021

Figure 32: 7MM, diagnosed prevalent cases (symptomatic) of hip OA by severity, both sexes, ages ≥18 years, N, 2021

Figure 33: Stepped-care approach for the treatment of OA

Figure 34: Unmet needs and opportunities in osteoarthritis

Figure 35: Overview of the development pipeline in osteoarthritis

Figure 36: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for osteoarthritis in the 7MM during 2021–31

Figure 37: Competitive assessment of the analgesic pipeline drugs benchmarked against the standards of care, NSAIDs and corticosteroids

Figure 38: Competitive assessment of the DMOAD pipeline drugs benchmarked against the standards of care, NSAIDs and corticosteroids

Figure 39: Analysis of the company portfolio gap in OA during the forecast period

Figure 40: Global (7MM) sales forecast by country for OA in 2021 and 2031

Figure 41: Sales forecast by class for OA in the US in 2021 and 2031

Figure 42: Sales forecast by class for OA in the 5EU in 2021 and 2031

Figure 43: Sales forecast by class for OA in Japan in 2021 and 2031

Frequently asked questions

Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2031 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2031 in real time.

  • Access a live Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.